abstract
The cardinal signs of Parkinson’s disease (PD) reflect striatal dopamine depletion due to the progressive degeneration of neurons arising from the substantia nigra. Initially, treatment with the dopamine precursor levodopa ordinarily confers substantial clinical benefit. Later, however, increasing difficulties arise mainly due to the appearance of motor response fluctuations and dyskinesias complicating the treatment of late-stage PD (1–6). Available evidence suggests that standard dopaminomimetic treatment regimens promote the intermittent activation of striatal dopaminergic receptors, which under normal conditions operate mainly tonically (7), and that this nonphysiologic stimulation favors the appearance of the motor fluctuations and dyskinesias (8).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hurtig, H. I. (1997) Problems with current pharmacologic treatment of Parkinson’s disease. Exp. Neurol. 144, 10–16.
Chase, T. N. (1998) The significance of continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Drugs 55, 1–9.
Metman, L. V., Locatelli, E. R., Bravi, D., Mouradian, M. M., and Chase, T. N. (1998) Apomorphine responses in Parkinson’s disease and the pathogenesis of motor complications. Neurology 50, 574–574.
Miyawaki, E. Lyons, K., Pahwa, R., Troster, A. I., Hubble, J., Smith, D., et al. (1997) Motor complications of chronic levodopa therapy in Parkinson’s disease. Clin. Pharmacol. 20, 523–530.
Chase, T. N. and Oh, J. D. (1999) Striatal mechanisms contributing to the pathogenesis of parkinsonian signs and levodopa-associated motor complications. Ann. Neurol. 47(snsuppl. 1), S112–S129.
Quinn, N. P. (1998) Classification of fluctuations in patients with Parkinson’s disease. Neurology 51(suppl 2), S25–S29.
Schultz, W. (1994) Behavior-related activity of primate dopamine neurons. Rev. Neurol. (Paris) 150, 634–639.
Chase, T. N., Oh, J. D., and Blanchet, P. J. (1998) Neostriatal mechanisms in Parkinson’s disease. Neurology 51, S30–S35.
Bravi, D., Mouradian, M. M., Roberts, J. W., Davis, T. L., Shon, Y. H., and Chase, T. N. (1994) Wearing-off fluctuations in Parkinson’s disease: contribution of postsynaptic mechanisms. Ann. Neurol. 36, 27–31.
Kotter, R. (1994) Postsynaptic integration of glutamatergic and dopaminergic sig-nals in the striatum. Prog. Neurobiol. 44, 163–196.
Engber, T. M., Papa, S. M., Boldry, R. C., and Chase, T. N. (1994) NMDA recep-tor blockade reverses motor response alterations induced by levodopa. NeuroReport 5, 2586–2588.
Engber, T. M, Papa, S. M., Boldry, R. C., and Chase, T. N. (1994) NMDA recep-tor blockade reverses motor response alterations induced by levodopa. NeuroReport 5, 2586–2588.
Papa, S. M., Boldry, R. C., Engber T. M., Kask, A. M., and Chase, T. N. (1995) Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res. 701, 13–18.
Cepeda, C. and Levine, M. S. (1998) Dopamine and N-methyl-D-aspartate recep-tor interactions in the neostriatum. Dev. Neurosci. 20, 1–18.
Wollmuth, L. P., Kuner, T., Seeburg, P. H., and Sakmann, B. (1996) Differential contribution of the NR1-and NR2A-subunits to the selectivity filter of recombi-nant NMDA receptor channels. J. Physilo. (London) 491, 779–797.
Ozawa, S, Kamiya, H., and Tsuzuki, K. (1998) Glutamate receptors in the mam-malian central nervous system. Prog. Neurobiol. 54, 581–618.
Chen, Q. and Reiner, A. (1996) Cellular distribution of the NMDA receptor NR2A/2B subunits in the rat striatum. Brain Res. 743, 346–352.
Gurd, J. W. (1997) Protein tyrosine phosphorylation: Implications for synap-tic function. Neurochem. Int. 31, 635–649.
Suen, P. C., Wu, K., Xu, J. L., Lin S. Y., Levine, E. S., and Black, I. B. (1998) NMDA receptor subunits in the postsynaptic density of rat brain: expression and phosphorylation by endogenous protein kinases. Brain Res. 59, 215–228.
Rostas, J. A. P., Brent, V. A., Voss, K., Errington, M. L., Bliss, T. V. P, and Gurd, J. W. (1996) Enhanced tyrosine phosphorylation of the 2B subunit of the N-methyl-D-aspartate receptor in long-term potentiation. Proc. Natl. Acad. Sci. USA 93, 10,452–10,456.
Sigel, E. (1995) Functional modulation of ligand-gated gaba(a) and NMDA receptor channels by phosphorylation. J. Recep. Sig. Transduc. Res. 15, 325–332.
Rosenblum, K., Berman, D. E., Hazvi, S., Lamprecht, R., and Dudai, Y. (1997) NMDA receptor and the tyrosine phosphorylation of its 2B subunit in taste learning in the rat insular cortex. J. Neurosci. 17, 5129–5135.
Rosenblum, K., Dudai, Y., and Levin, G. R. (1996) Long-term potentiation increases tyrosine phosphorylation of the N-methyl-D-aspartate receptor subunit 2B in rat dentate gyrus in vivo. Proc. Natl. Acad. Sci. US. 93, 10,457–10,460.
Takagi, N., Shinno, K., Teves, L., Bissoon, N., Wallace, M. C., and Gurd, J. W. (1997) Transient ischemia differentially increases tyrosine phosphorylation of NMDA receptor subunits 2A and 2B. J. Neurochem. 69, 1060–1065.
Stefani, A., Pisani, A., Bernardi, G., Bonci, A., Mercuri, N. B., Stratta, F., and Calabresi, P. (1995) The modulation of dopamine receptors in rat striatum. J. Neural. Transm. Supp. 45, 61–66.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Humana Press Inc.
About this protocol
Cite this protocol
Oh, J.D. (2001). Regulation of Striatal N-Methyl-D-Aspartate Receptor (NMDAR) Function by Phosphorylation of its Subunits in Parkinsonian Rats. In: Maral Mouradian, M. (eds) Parkinson's Disease. Methods in Molecular Medicine™, vol 62. Humana Press. https://doi.org/10.1385/1-59259-142-6:247
Download citation
DOI: https://doi.org/10.1385/1-59259-142-6:247
Publisher Name: Humana Press
Print ISBN: 978-0-89603-761-8
Online ISBN: 978-1-59259-142-8
eBook Packages: Springer Protocols